Receive our newsletter – data, insights and analysis delivered to you
  1. Research Reports
December 15, 2016

Report: Cancer immunotherapies market projected to grow fourfold to reach $75.8bn by 2022

The cancer immunotherapies market is projected to witness rapid growth at a compound annual growth rate (CAGR) of 23.9%, according to a report by GBI Research.

The cancer immunotherapies market is projected to witness rapid growth at a compound annual growth rate (CAGR) of 23.9%, according to a report by GBI Research.

Titled ‘Global Cancer Immunotherapies Market to 2022’, the report forecasts the cancer immunotherapies market to increase from $16.9bn in 2015 to $75.8bn by 2022.

"A number of late-stage products and already marketed drugs are expected to achieve blockbuster status during the forecast period."

There are currently 2,037 products in development, with the majority being early stage products indicating the hurdles associated with progressing development, from pre-clinical to clinical stage.

The imbalance between early stage and late-stage products reflects the difficulties in developing cancer immunotherapies, notes Yasser Mushtaq, Senior Analyst for GBI Research. Despite the hurdles, there is a strong interest towards investment in the therapy class, which may help in moving products from early stage to late-stage development.

A number of late-stage products and already marketed drugs are expected to achieve blockbuster status during the forecast period. AstraZeneca’s durvalumab and tremelimumab, Novartis’ CTL-019 and Kite Pharma’s KTE-C19 CAR are some of the notable products anticipated to achieve blockbuster status.

A number of existing blockbuster therapies such as Revlimid, Opdivo, Keytruda and Gazyva are also expected to achieve strong revenue growth. Revenues of Keytruda and Opdivo are projected to rise by $7bn and $9bn respectively, while Revlimid is also projected to achieve similar levels of growth, adds Mushtaq.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU